Abstract: Polyethylene glycol ethers of alkyl alcohols having the general formula CH3(CH2)xCH2(OCH2CH2)nOH wherein x is 8 to 20 (of which ceteareth-20, steareth-20 and steareth-100 are preferred), poloxamer 185, poloxamer 407, N,N-dimethyl dodecylamine N-oxide, and mixtures thereof, are employed to increase follicular delivery and/or follicular residence time of certain water soluble ornithine decarboxylase inhibitors of which 2(difluoromethyl)-2,5-diamino pentanoic acid and its pharmaceutically acceptable salts, hydrates, optical enantiomers and racemic mixture are preferred.

Abstract: There is disclosed a class of pharmaceutical compositions useful for the treatment of cancer, particularly solid tumors, and having a mechanism of action as spermine antagonists. The present pharmaceutical compositions are able to inhibit the inhibitory effect of spermine upon macrophage function, and thus prevent spermine-induced immunosuppression.

Abstract: The present invention is concerned with new, previously unsuggested, therapeutic uses of dl-THP (dl-tetrahydropalmatine).

Abstract: 20-HETE agonists and antagonists are disclosed along with therapeutic applications. In a preferable form of the invention, the 20-HETE agonists are selected from the group consisting of 21-hydroxyheneicosa-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid, 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid and 20-,21-dimethyl 20-HETE. Preferable 20-HETE antagonists include 5(S)-HETE, 15(S)-HETE, 19(S)-HETE, 19-hydroxynonadeca-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid and 20-hydroxyeicosa 6(Z),15(Z)-dienoic acid.

Abstract: Described in the present invention are a dispersion which comprises, as a dispersoid, (a) 5 to 40 wt. % of an amphipatic lipid containing, in the molecule thereof, at least one hydroxy and amide group, and (b) 2 to 55 wt. % of a surfactant in an aqueous medium; a washing-away type cosmetic composition comprising the dispersion; and a washing-away type cosmetic composition comprising (A) 0.01 to 10 wt. % of an amphipatic lipid which contains, in the molecule thereof, at least one hydroxy and amide group and having a melting point not less than 30° C. and (B) 5 to 95 wt. % of a surfactant. The dispersion according to the present invention is useful as a component of a washing-away type cosmetic composition having both an emulsion-like or pearl-lustrous appearance and low skin irritation.

Abstract: A chemical composition and method of use of the composition is described. The chemical composition includes an aza-enediyne, aza-enyne allene, or an aza-diallene. These compound are preferably non-hydrolyzable, cationic compounds that bind to nucleic acids. In addition it is believed that these compounds may undergo chemical reactions in the presence of a nucleic acid to generate reactive intermediates that cleave nucleic acids.

Abstract: The present invention relates to the use of a group of propargylamines of the general formula (I) wherein R1 is hydrogen or CH3 and R2 is (CH2)nCH3 and n is an integer from 0 to 16, and salts thereof, as cellular rescue agents in the treatment and prevention of diseases in which cell death occurs by apoptosis. Some of the compounds of formula I are novel. The invention is also directed to the use of these compounds in the treatment of these diseases, as well as to processes for the preparation of the compounds.

Abstract: There is disclosed a class of pharmaceutical compositions useful for the treatment of cancer, particularly solid tumors, and having a mechanism of action as spermine antagonists. The present pharmaceutical compositions are able to inhibit the inhibitory effect of spermine upon macrophage function, and thus prevent spermine-induced immunosuppression.

Abstract: Iodopropargylamine compound of the general formula (1): ##STR1## wherein R.sup.1 and R.sup.2 each independently represent a hydrogen atom or an alkyl group having 1 to 3 carbon atoms, or R.sup.1 and R.sup.2 combine with each other to form a tetramethylene group or a pentamethylene group, R.sup.3 represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms, and X and Y each independently represent a cyano group, an alkoxycarbonyl group having 2 to 7 carbon atoms, an alkylcarbonyl group having 2 to 7 carbon atoms, an alkylsulfonyl group having 1 to 6 carbon atoms, a phenylcarbonyl group or a phenylsulfonyl group, provided that the phenyl group of a phenylcarbonyl group or a phenylsulfonyl group may be optionally substituted by halogen atoms, alkyl groups having 1 to 3 carbon atoms, alkoxy groups having 1 to 3 carbon atoms, nitro groups or trifluoromethyl groups.

Abstract: The invention described here concerns the unique utility of fatty acids and their derivatives to eradicate existing fungal and bacterial infections in plants. Also, described herein are combination treatments whereby fatty acids are used to enhance or augment the activity of fungicides, bactericides, and biological control agents.

Abstract: The present invention relates to the use of calcium L-threonate, namely, to a method for preventing, inhibiting and curing osteoporosis and rickets using calcium L-threonate.

Abstract: Methods are provided for conducting surgical procedures in a patient wherein, during the surgical procedure, autonomous ventricular electrical conductivity and escape beats are reversibly and transiently suppressed to facilitate the surgical procedure. Also provided are compositions which are capable of inducing ventricular asystole in a patient. The compositions may include an AV node blocker. In one embodiment, compositions including an atrioventricular (AV) node blocker and a .beta.-blocker are provided, wherein the .beta.-blocker is present in an amount sufficient to substantially reduce the amount of AV node blocker required to induce ventricular asystole in the patient. The compositions and methods may be used for inducing temporary ventricular asystole in a beating heart, and to facilitate the performance of a variety of surgical techniques, including minimally invasive microsurgical techniques.

Abstract: Use of at least one aminothiol ester derivative for the preparation of a pharmaceutical composition intended to increase the inhibition of a character resistant to the induction of apoptosis of transformed cells, this character being due to the bc12 gene present in these cells. The pharmaceutical composition is more particularly intended to treat pathologies chosen from breast cancers, B cell lymphomas, leukaemias, neuroblastomas, adenocarcinomas of the prostate, prolactinomas and other pituitary adenomas.

Abstract: The present invention is based on the discovery of a metabolic pathway in which a specific kinase converts fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction. Fructose-lysine-3-phosphate (FL3P) is then broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins), which are believed to be a cause of diabetic complications. Disclosed is a class of compounds which inhibit the action of FL3P kinase in the above-mentioned pathway.

Abstract: In a method for treating or preventing allergy or allergic disorders an effective amount of a compound that inhibits intracellular generation of phosphatidic acid and diacylglycerol is administered. The intracellular generation of phosphatidic acid and diacylglycerol results from allergen presentation or mast cell/basophil activation.

Abstract: The present invention provides a method for treating pulmonary disease. More specifically, the present invention provides a method for treating diseases such as adult respiratory distress syndrome which result in oxidative stress that damages the cells of the lung. Pursuant to present invention, a method is provided that increases the intracellular glutathione levels of at least the cells of the lungs of a patient with pulmonary disease. To this end, a non-cysteine substrate that is a precursor for the intracellular synthesis of glutathione is administered to the patient.

Abstract: A preventive agent against adhesion of a marine organism comprising: at least one amine compound represented by the following formula (I): ##STR1## , wherein R is a C.sub.8-22 saturated or unsaturated aliphatic hydrocarbon group, R.sup.1 is hydrogen atom, aminopropyl, a C.sub.1-22 saturated aliphatic hydrocarbon or C.sub.2-22 unsaturated aliphatic hydrocarbon group, R.sup.2 is aminopropyl, a C.sub.1-8 saturated aliphatic hydrocarbon or C.sub.2-8 unsaturated aliphatic hydrocarbon group, provided that R.sup.1 is hydrogen atom or aminopropyl group when R.sup.2 is represents aminopropyl group, or a salt thereof; and at least one N-alkyl polyamine compound represented by the following formula (II):R--?NH(CH.sub.2).sub.3 !.sub.n --NH.sub.2 (II), wherein R is a C.sub.8-22 saturated or unsaturated aliphatic hydrocarbon group and n is an integer from 2 to 4, or a salt thereof in an amount of 0.1 to 9 parts by weight to one part by weight of the compound (I).

Abstract: Disclosed are methods for rectifying or ameliorating abnormal responses of mammalian immune systems. Also disclosed are methods for modifying normal responses of the mammalian immune system. Further disclosed are methods for accomplishing the foregoing by administering to a mammal a prolactin reducer and/or enhancer at a pre-determined time or times during a 24-hour period that results in modification of the mammal's abnormal prolactin profile so that it approaches or conforms to the prolactin profile of a young, healthy mammal of the same species (or to a standard profile generated from such individuals). Additionally, methods of upregulating or augmenting an immune response in a mammal are disclosed.

Abstract: A non-toxic, environmentally safe and easily employable insecticide and insect repellant is achieved by providing an aqueous composition incorporating ethanolamine based compounds, either independently or in combination with the ethanolamine based compounds being selected from both simple compounds and conjugated compounds. In one preferred embodiment, a highly effective composition is attained for safe, effective, direct topical application to humans and animals by employing between about 10% and 70% by volume of the entire composition of the ethanolamine-based compound. In alternate preferred embodiments, the insecticide is formulated for application to plants, trees, crops, and other vegetation to provide a composition which effectively controls bothersome insects, while being completely safe and non-injurious to the plant, tree, or crop, as well as to the flowers or fruit thereof.

Abstract: Baits useful for controlling lepidoptera populations is made with (a) a diet component for lepidoptera; (b) a toxicant; (c) a chemiluminescent, visual attractant and (d) an encapsulating agent that will allow moisture to permeate and form an external condensate of said diet and said toxicant. The diet, toxicant, and chemiluminescent visual attractant can be used in the same bait particle in a homogeneous or layered structure. Alternatively, the diet/toxicant may be used with a first encapsulating agent in a first bait particle with the chemiluminescent, visual attractant encapsulated in a second bait particle and distributed among the diet/toxicant bait particles.

Abstract: A method is provided for controlling the proliferation of molluscs in target habitat by applying to the habitat a compound or mixture of compounds which are amines, ethoxylated amines, quaternary amines, ethoxylated quaternary amines and cyclic amines.

Abstract: Compounds having the formula (I) below:(R.sub.1 R.sub.2 N)CH.sub.2 --CH.dbd.CH--CH.sub.2 (NR.sub.3 R.sub.4)(I)wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4, which may be the same or different represent hydrogen atoms, an alkyl group having from 1 to 6 carbon atoms, a cycloalkyl group of 3 to 6 carbon atoms, a heterocyclic group, an aryl group, a heteroaryl group having from 3 to 6 atoms, an amidino group or R.sub.1, R.sub.2 and/or R.sub.3 and R.sub.4 together represent a carbocyclic or heterocyclic group comprising from 3 to 6 atoms with the proviso that R.sub.1, R.sub.2, R.sub.3 and R.sub.4 cannot simultaneously represent hydrogen and salts thereof are fungicides especially mildewicides. Preferred compounds are those wherein the groups R represent methyl or ethyl groups.

Abstract: Treatment and prophylaxis of endotoxin caused toxicity is disclosed. This is accomplished by administering phospholipid containing compositions to the subject. The compositions are protein and peptide free, and may contain triglycerides, or other polar or neutral lipids.

Abstract: A pharmaceutical or cosmetic composition is disclosed comprising in combination a retinoid and a sterol capable of inhibiting the biosynthesis of cholesterol resulting in a synergistic effect in the treatment of disorders of epidermic keratinization, proliferation and/or sebaceous function.

Abstract: Selegiline and pharmaceutically acceptable analog forms thereof are used as treatments for hearing loss in mammals, especially dogs.

Abstract: Provided is a method for treating inflammatory bowel disease in mammals utilizing certain phenol and benzamide compounds.

Abstract: The invention relates to a series of propargylamines, their salts and pharmaceutical compositions containing a compound of formula (III) wherein R.sub.1, R.sub.3 and R.sub.4 are the same or different and represent hydrogen or a straight chain or branched lower alkyl; y is an integer ranging from 0 to 5; z is an integer ranging from 0 to 5; and R.sub.2 is a straight chain or branched alkyl, alkenyl, alkynyl, alkoxy, alkylthio or alkyl sulphinyl group having from 3 to 11 carbon atoms, said group being unsubstituted or substituted with at least one of the substituents selected from hydroxy, aldehyde, oxo, loweracyloxy, halogen, thio, sulfoxide, sulfone, phenyl, halogen-substituted phenyl, hydroxy-substituted phenyl, cycloalkyl having from 3 to 6 carbon atoms and heterocyclic substituents having between 3 and 6 atoms, of which form 1 to 3 are heteroatoms selected from O, S and/or N, and pharmaceutically acceptable salts thereof, in admixture with a pharmaceutically acceptable carrier, excipient or adjuvant.

Abstract: The use of (E)-2-butene-1,4-diamine or a salt thereof with inorganic or organic acids, as a fungicide.

Abstract: Fluorinated alkene compounds useful for and methods of controlling nematodes, insects, and acarids that prey on agricultural crops. Polar compounds, for example, 3,4,4-trifluoro-3-butene-1-amine or 3,4,4-trifluoro-3-butenoic acid, are particularly useful for systemic control of pests. Novel method and intermediates for the preparation of 3,4,4-trifluoro-3-butene-1-amine are also provided.

Abstract: Amino derivatives represented by the following general formula (1): ##STR1## and external skin care preparations containing such an amide derivative, are useful for preventing or curing skin roughness. Intermediates useful for the preparation of such amides are also disclosed.

Abstract: Propargylamine derivatives having the general formula: ##STR1## wherein R is a hydrogen atom, an unsubstituted phenyl group or a phenyl group substituted with halogen, trifluoromethyl, loweralkoxy, nitro, cyano, amido or N,N-diloweralkylamido, R.sub.1, R.sub.2 or R.sub.3 are the same or different and each represent a hydrogen atom or a loweralkyl group, R.sub.4 is a hydrogen atom or a loweralkyl, benzyl, phenethyl or furyl group, or R.sub.3 and R.sub.4 together with the nitrogen atom to which they are attached form a piperidinyl group, and their pharmaceutically acceptable acid addition salts, have been found to be useful in the treatment of anxiety, psychotic states and aggressive behavior in affected animals.

Abstract: Compounds of the formula ##STR1## wherein X is O or CH.sub.2 ; Y is O, --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH--, --C.tbd.C--, or --OCH.sub.2 C.sub.6 H.sub.4 --;Z is --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH-- or --C.tbd.C--;f, h, k, m and t, independently, are 0 or 1;n is an integer from 1 to 12;R.sup.1 is hydrogen, lower alkyl, lower alkenyl, cycloalkyl, or aralkyl; and A is B or --O--B, wherein B is a mono-, di- or tricyclic aromatic or heteroaromatic moiety substituted by the group --COR.sup.2, --(O).sub.t --(W).sub.s --COR.sup.2 or --(CH.dbd.CH).sub.p COR.sup.2 and which may also contain up to 4 additional substituents selected, independently, from the group consisting of halogen, cyano, lower alkyl, lower alkoxy, sulfonamido, alkanoyl, aroyl, --(Q).sub.k --(W).sub.s' --E or --(Q).sub.k --(W).sub.s" --C.sub.6 H.sub.4 --(W).sub.s'" --E, provided that no more than one of said substituents is --(Q).sub.k --(W).sub.s' --E or --(Q).sub.k --(W).sub.s" --C.sub.6 H.sub.4 --(W).sub.s'" --E, and wherein E is COR.sup.

Abstract: A transdermal flux enhancing pharmaceutical composition for transdermal administration to a human or lower animal subject comprising a safe and effective amount of a pharmacologically active compound or a prodrug thereof, an aqueous solvent system comprising from about 15 to 75% by volume of one or more water miscible solvents, and a penetration enhancer selected from certain 1-alkylazacycloheptan-2-ones and cis-olefin compounds of the formulaCH.sub.3 (CH.sub.2).sub.x CH.dbd.CH(CH.sub.2).sub.y R.sup.3where R.sup.3 is CH.sub.2 OH, CH.sub.2 NH.sub.2 or COR.sup.4 and R.sup.4 is OH or (C.sub.1 -C.sub.4)alkoxy, x and y are each an integer from 3 to 13 and the sum of x and y is from 10 to 16; methods for their use in treating various illnesses in a human or lower animal by transdermal administration of said composition.

Abstract: The present invention relates to an agent or concentrate for protecting sawn timber against wood-discolouring fungi, containing a fungicide on phenol basis and a fungicide on organo-iodine basis, optionally fungicides and insecticides, dissolved in an organochemical solvent or solvent mixture or in a mixture of water and organochemical solvent or solvent mixture and at least one emulsifier.

Abstract: A fortified glutaraldehyde compound with and without dual synergistic phenols is provided for disinfection and sanitization. One formula consists of: glutaraldehyde; dual quaternary ammonium chloride (n-alkyl dimethylethylbenzyl ammonium chloride and n-alkyl dimethylbenzyl ammonium chloride); para tertiary amyl phenol; ortho phenyl phenol; citric or acetic acid; sodium citrate; isopropyl or ethyl alcohol; triethanol amine-HCl; and water in the following proportions: 25.00 to 42.00 grams; 25.00 grams; 1.00 gram; 1.00 gram; 0.50 grams; 0.25 grams; 14.00 grams; 1.00 gram; and 32.25 to 15.25 grams. The formula for environmentally protected uses consists of: glutaraldehyde; dual quaternary ammonium chloride (n-alkyl dimethylethylbenzyl ammonium chloride and n-alkyl dimethylbenzyl ammonium chloride); citric or acetic acid; sodium citrate; isopropyl or ethyl alcohol; triethanol amine-HCl; and water in the following proportions: 25.00 to 42.00 grams; 25.00 grams; 0.50 grams; 0.25 grams; 14.00 grams; 1.

Abstract: A lenitive composition is provided for application to the skin of an anthralin patient for reducing anthralin-induced inflammation and the staining associated with anthralin use. The lenitive composition is a single phase aqueous treating solution comprising an organic amine and a film-forming agent dissolved within a nontoxic dermatologically acceptable carrier. The organic amine is selected from the group consisting of lower alkyl and lower alkanol primary, secondary and tertiary amines and comprises about 1 to 25 percent by weight of the single phase aqueous treating solution. The solution is topically applied to the anthralin-treated areas so as to completely cover the treated areas. The solution is applied before or after anthralin wash off, preferably in the form of a fine spray or mist.

Abstract: This invention relates to certain inhibitors of lysyl oxidase and their use in the treatment of diseases and conditions associated with the abnormal deposition of collagen.

Abstract: A component having the following formula I: ##STR1## wherein X represents an integer ranging from 1 to 2 or 7 to 13;Y represents an integer ranging from 0 to 5;Z represents an integer ranging from 0 to 5;R.sub.1, R.sub.2 and R.sub.3 are the same or different and represent H or a straight chain or branched lower alkyl; andR' and R" are the same or different and represent H or halogen,and pharmaceutically acceptable salts thereof. Preferably, the lower alkyl has between 1 and 4 carbon atoms and the halogen is selected from the group consisting of fluorine, chlorine, bromine and iodine. The compound is useful as a MAO-B inhibitor. Also within the scope of the present invention is a composition for the inhibition of MAO-B activity and a method for alleviating Parkinsonism, Alzheimer's disease, depression, attention deficit hyperactive disorders, aging and other neuropsychiatric disorders and for improving the quality of life.

Abstract: The rate and character of mammalian hair growth is altered by topical application to the skin of a composition containing a dermatologically acceptable carrier and an inhibitor of S-adenosylmethionine decarboxylase with or without an ornithine decarboxylase inhibitor.

Abstract: This invention relates to certain inhibitors of lysyl oxidase and their use in the treatment of diseases and conditions associated with the abnormal deposition of collagen.

Abstract: This invention relates to certain inhibitors of lysyl oxidase and their use in the treatment of diseases and conditions associated with the abnormal deposition of collagen.

Abstract: This invention relates to certain inhibitors of lysyl oxidase and their use in the treatment of diseases and conditions associated with the abnormal deposition of collagen.

Abstract: The importance of polyamines in biological systems is discussed as well as the implications of polyamines in the treatment of various diseases. Novel N-substituted-2,3-butadienyl tri- and tetra-aminoalkanes are disclosed as well as their use inthe treatment of diseases and the pharmaceutical compositions.

Abstract: Noninfectious inflammatory skin diseases in which bacteria or yeasts play a significant adjunctive role are treated with topical formulations of aliphatic amines containing 9 to 18 carbon atoms, and pharmaceutically acceptable salts thereof.

Abstract: 1. A compound of the formula:H.sub.2 C.dbd.C.dbd.CHCH.sub.2 NHCH.sub.2 --Z--CH.sub.2 NHRwherein:Z is --CH.sub.2 CH.sub.2 -- or trans--CH.dbd.CH--,R is H, CH.sub.3 --, CH.sub.3 CH.sub.2, CH.sub.3 (CH.sub.2).sub.2 --, --(CH.sub.2).sub.3 NH.sub.2, --(CH.sub.2).sub.3 NHCOCH.sub.3, --CH.sub.2 CH.dbd.CH.sub.2, or --CH.sub.2 CH.dbd.C.dbd.CH.sub.2, or a pharmaceutically acceptable acid addition salt thereof are inhibitors of polyamine oxidase.

Abstract: The rate and character of human hair growth including androgen-stimulated beard hair growth in intact, sexually mature males is altered by the topical application out of a dermatologically acceptable carrier of a material capable of inhibiting the action of the enzyme ornithine decarboxylase. In a preferred practice of the invention, compositions containing such materials along with anti-androgen material are employed.

Abstract: Novel fluorinated diaminoalkyne derivatives are inhibitors of ornithine decarboxylase enzyme and have the following general Formula I: ##STR1## wherein R represents C.sub.1 -C.sub.4 alkyl, or preferably, hydrogen.

Abstract: Novel nonaromatic fluoroallylamines are potent MAO inhibitors and at low dose selectively inhibit MAO-B. They are useful in the treatment of depression and coadministered with L-dopa, in the treatment of Parkinsonism.

Abstract: This invention relates to new isoprenylamine derivatives and acid addition salts thereof, which are useful as medicines for controlling virus infection of vertebrate animals, or the intermediates therefor.

Abstract: The compound of the formula: ##STR1## wherein R.sub.1 is hydrogen, methyl or hydroxymethyl, R.sub.2 is hydrogen or methoxy, R.sub.3 is hydroxy or methoxy, and R.sub.4 is hydrogen or a group ##STR2## is novel, and the compound is of use as inhibitors of animal tissue fibrosis, or biochemical reagents.